Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: Review of the literature

Jun Iwamoto, Yoshihiro Sato, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of the present review was to clarify the efficacy of currently available potent antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk. PubMed was used to search the literature for randomized controlled trials (RCTs), with the following search terms: fracture, etidronate, alendronate, risedronate, minodronate, raloxifene, bazedoxifene and Japan. The inclusion criteria were papers written in English, ≥50 subjects per group and a study period of ≥1 year. Fourteen RCTs met these criteria. The efficacy of antiresorptive agents for preventing vertebral, nonvertebral and hip fractures was investigated. There was evidence that raloxifene reduced the incidence of clinical vertebral fractures, while etidronate, alendronate and minodronate (but not bazedoxifene) reduced the incidence of morphometric vertebral fractures in patients with postmenopausal or involutional osteoporosis. Head-to-head trials showed that alendronate and raloxifene had similar efficacy for preventing vertebral fractures in patients with postmenopausal osteoporosis, while risedronate was not inferior to etidronate for reducing the incidence of morphometric vertebral fractures in patients with involutional osteoporosis. Alendronate reduced the incidence of hip fractures in patients with Parkinsons disease, and risedronate reduced the incidence of nonvertebral fractures and hip fractures in patients with Alzheimers disease or stroke. In conclusion, the present review confirmed the efficacy of etidronate, minodronate and raloxifene for the prevention of vertebral fractures, the efficacy of alendronate for vertebral and hip fractures, and the efficacy of risedronate for vertebral, nonvertebral and hip fractures in Japanese patients with an increased fracture risk.

Original languageEnglish
Pages (from-to)191-203
Number of pages13
JournalDrugs and Aging
Volume29
Issue number3
DOIs
Publication statusPublished - 2012

Fingerprint

Bone Density Conservation Agents
Alendronate
Etidronic Acid
Hip Fractures
Incidence
Postmenopausal Osteoporosis
Osteoporosis
Randomized Controlled Trials
PubMed
Parkinson Disease
Japan
Alzheimer Disease
Stroke
Risedronate Sodium
Raloxifene Hydrochloride

Keywords

  • Alendronic-acid
  • Bazedoxifene
  • Bisphosphonates
  • Bone-resorption-factor- inhibitors
  • Elderly
  • Etidronic-acid
  • Fracture
  • Hip-fracture
  • Minodronic-acid
  • Osteoporosis
  • Osteoporosis-therapies
  • Raloxifene
  • Risedronic-acid
  • Selective-estrogen-receptor-modulators
  • Vertebral-fracture.

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology

Cite this

Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk : Review of the literature. / Iwamoto, Jun; Sato, Yoshihiro; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Drugs and Aging, Vol. 29, No. 3, 2012, p. 191-203.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Sato, Yoshihiro ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk : Review of the literature. In: Drugs and Aging. 2012 ; Vol. 29, No. 3. pp. 191-203.
@article{ad144b0440924f65b2104299c8541c98,
title = "Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: Review of the literature",
abstract = "The aim of the present review was to clarify the efficacy of currently available potent antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk. PubMed was used to search the literature for randomized controlled trials (RCTs), with the following search terms: fracture, etidronate, alendronate, risedronate, minodronate, raloxifene, bazedoxifene and Japan. The inclusion criteria were papers written in English, ≥50 subjects per group and a study period of ≥1 year. Fourteen RCTs met these criteria. The efficacy of antiresorptive agents for preventing vertebral, nonvertebral and hip fractures was investigated. There was evidence that raloxifene reduced the incidence of clinical vertebral fractures, while etidronate, alendronate and minodronate (but not bazedoxifene) reduced the incidence of morphometric vertebral fractures in patients with postmenopausal or involutional osteoporosis. Head-to-head trials showed that alendronate and raloxifene had similar efficacy for preventing vertebral fractures in patients with postmenopausal osteoporosis, while risedronate was not inferior to etidronate for reducing the incidence of morphometric vertebral fractures in patients with involutional osteoporosis. Alendronate reduced the incidence of hip fractures in patients with Parkinsons disease, and risedronate reduced the incidence of nonvertebral fractures and hip fractures in patients with Alzheimers disease or stroke. In conclusion, the present review confirmed the efficacy of etidronate, minodronate and raloxifene for the prevention of vertebral fractures, the efficacy of alendronate for vertebral and hip fractures, and the efficacy of risedronate for vertebral, nonvertebral and hip fractures in Japanese patients with an increased fracture risk.",
keywords = "Alendronic-acid, Bazedoxifene, Bisphosphonates, Bone-resorption-factor- inhibitors, Elderly, Etidronic-acid, Fracture, Hip-fracture, Minodronic-acid, Osteoporosis, Osteoporosis-therapies, Raloxifene, Risedronic-acid, Selective-estrogen-receptor-modulators, Vertebral-fracture.",
author = "Jun Iwamoto and Yoshihiro Sato and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2012",
doi = "10.2165/11597480-000000000-00000",
language = "English",
volume = "29",
pages = "191--203",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk

T2 - Review of the literature

AU - Iwamoto, Jun

AU - Sato, Yoshihiro

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2012

Y1 - 2012

N2 - The aim of the present review was to clarify the efficacy of currently available potent antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk. PubMed was used to search the literature for randomized controlled trials (RCTs), with the following search terms: fracture, etidronate, alendronate, risedronate, minodronate, raloxifene, bazedoxifene and Japan. The inclusion criteria were papers written in English, ≥50 subjects per group and a study period of ≥1 year. Fourteen RCTs met these criteria. The efficacy of antiresorptive agents for preventing vertebral, nonvertebral and hip fractures was investigated. There was evidence that raloxifene reduced the incidence of clinical vertebral fractures, while etidronate, alendronate and minodronate (but not bazedoxifene) reduced the incidence of morphometric vertebral fractures in patients with postmenopausal or involutional osteoporosis. Head-to-head trials showed that alendronate and raloxifene had similar efficacy for preventing vertebral fractures in patients with postmenopausal osteoporosis, while risedronate was not inferior to etidronate for reducing the incidence of morphometric vertebral fractures in patients with involutional osteoporosis. Alendronate reduced the incidence of hip fractures in patients with Parkinsons disease, and risedronate reduced the incidence of nonvertebral fractures and hip fractures in patients with Alzheimers disease or stroke. In conclusion, the present review confirmed the efficacy of etidronate, minodronate and raloxifene for the prevention of vertebral fractures, the efficacy of alendronate for vertebral and hip fractures, and the efficacy of risedronate for vertebral, nonvertebral and hip fractures in Japanese patients with an increased fracture risk.

AB - The aim of the present review was to clarify the efficacy of currently available potent antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk. PubMed was used to search the literature for randomized controlled trials (RCTs), with the following search terms: fracture, etidronate, alendronate, risedronate, minodronate, raloxifene, bazedoxifene and Japan. The inclusion criteria were papers written in English, ≥50 subjects per group and a study period of ≥1 year. Fourteen RCTs met these criteria. The efficacy of antiresorptive agents for preventing vertebral, nonvertebral and hip fractures was investigated. There was evidence that raloxifene reduced the incidence of clinical vertebral fractures, while etidronate, alendronate and minodronate (but not bazedoxifene) reduced the incidence of morphometric vertebral fractures in patients with postmenopausal or involutional osteoporosis. Head-to-head trials showed that alendronate and raloxifene had similar efficacy for preventing vertebral fractures in patients with postmenopausal osteoporosis, while risedronate was not inferior to etidronate for reducing the incidence of morphometric vertebral fractures in patients with involutional osteoporosis. Alendronate reduced the incidence of hip fractures in patients with Parkinsons disease, and risedronate reduced the incidence of nonvertebral fractures and hip fractures in patients with Alzheimers disease or stroke. In conclusion, the present review confirmed the efficacy of etidronate, minodronate and raloxifene for the prevention of vertebral fractures, the efficacy of alendronate for vertebral and hip fractures, and the efficacy of risedronate for vertebral, nonvertebral and hip fractures in Japanese patients with an increased fracture risk.

KW - Alendronic-acid

KW - Bazedoxifene

KW - Bisphosphonates

KW - Bone-resorption-factor- inhibitors

KW - Elderly

KW - Etidronic-acid

KW - Fracture

KW - Hip-fracture

KW - Minodronic-acid

KW - Osteoporosis

KW - Osteoporosis-therapies

KW - Raloxifene

KW - Risedronic-acid

KW - Selective-estrogen-receptor-modulators

KW - Vertebral-fracture.

UR - http://www.scopus.com/inward/record.url?scp=84857873905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857873905&partnerID=8YFLogxK

U2 - 10.2165/11597480-000000000-00000

DO - 10.2165/11597480-000000000-00000

M3 - Article

C2 - 22372723

AN - SCOPUS:84857873905

VL - 29

SP - 191

EP - 203

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 3

ER -